Eledon Pharmaceuticals (ELDN) Expected to Announce Earnings on Wednesday

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Eledon Pharmaceuticals to post earnings of ($0.22) per share for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.Get Eledon Pharmaceuticals alerts:Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last released its earnings results on Thursday, March 19th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.10. Eledon Pharmaceuticals Stock PerformanceNASDAQ ELDN opened at $3.78 on Wednesday. The business's 50 day moving average is $3.06 and its two-hundred day moving average is $2.48. Eledon Pharmaceuticals has a 12-month low of $1.35 and a 12-month high of $4.60. The stock has a market capitalization of $286.72 million, a price-to-earnings ratio of -7.27 and a beta of 0.94. Wall Street Analysts Forecast GrowthSeparately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Eledon Pharmaceuticals in a research report on Friday, March 27th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $9.67.View Our Latest Stock Report on ELDNInstitutional Investors Weigh In On Eledon PharmaceuticalsSeveral institutional investors have recently modified their holdings of ELDN. BNP Paribas Financial Markets boosted its stake in shares of Eledon Pharmaceuticals by 143.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,154 shares of the company's stock worth $31,000 after acquiring an additional 7,166 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $36,000. Virtu Financial LLC purchased a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $39,000. Cetera Investment Advisers boosted its stake in shares of Eledon Pharmaceuticals by 72.9% during the 4th quarter. Cetera Investment Advisers now owns 26,584 shares of the company's stock worth $40,000 after acquiring an additional 11,207 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $45,000. Hedge funds and other institutional investors own 56.77% of the company's stock. Eledon Pharmaceuticals Company Profile (Get Free Report)Eledon Pharmaceuticals, Inc NASDAQ: ELDN is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders. Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.Featured ArticlesFive stocks we like better than Eledon PharmaceuticalsThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Eledon Pharmaceuticals Right Now?Before you consider Eledon Pharmaceuticals, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.While Eledon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here